Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer
20 Maio 2008 - 7:00AM
PR Newswire (US)
HAYWARD, Calif., May 20 /PRNewswire-FirstCall/ -- Kosan Biosciences
Incorporated (NASDAQ:KOSN) today announced the appointment of
Pamela S. Cohen, M.D., as Senior Vice President and Chief Medical
Officer. Dr. Cohen is a recognized expert in the global development
and registration of cancer therapeutics and has had a long and
distinguished career as a medical oncologist and clinical
pharmacologist, most notably at Novartis. Dr. Cohen joins Kosan
from GE Healthcare Medical Diagnostics where she served as the
Global Oncology Therapeutic Area Head, responsible for strategic
development, clinical trial implementation and registration of the
GE Healthcare-Medical Diagnostics Division's product portfolio of
molecularly targeted imaging diagnostics. "Pam's extensive
experience in leading all aspects of cancer drug development and
registration in worldwide markets and her work with a broad range
of compound classes and tumor types will be of significant value to
Kosan as we advance our Hsp90 inhibitor and epothilone programs
through later stages of development," said Helen S. Kim, Kosan's
President and Chief Executive Officer. "Recruiting an experienced
and accomplished chief medical officer was one of Kosan's major
goals for 2008. We are delighted that Pam will be able to leverage
her direct knowledge of cytotoxic and targeted oncology drug
development to bring leadership, direction and focus to the
execution of Kosan's development activities. Pam is well-known and
respected throughout the oncology community as well as the
pharmaceutical industry, and she will be instrumental in
strengthening our partnering initiatives. Kosan's Board of
Directors and management team join me in welcoming Pam to Kosan."
Dr. Cohen has been involved in the global development and
successful registration of several well-established cancer
therapeutics. At Novartis, she served for close to 8 years in
positions of increasing responsibility, including Executive
Director, Oncology, where she was responsible for the supplemental
new drug application (sNDA) registration filing of Gleevec(TM) in
Ph+ adult acute lymphoblastic leukemia (ALL) and, as global
clinical project leader, successfully brought the first FLT3 kinase
inhibitor PKC412 (Midostaurin) to Phase 3 in acute myelogenous
leukemia (AML). Earlier in her career at Novartis, Dr. Cohen was
responsible for the early clinical development through Phase 1 and
proof-of-concept at Novartis Oncology, and was an early proponent
of the use of biomarkers to speed clinical decision making and
optimize trial design. Dr. Cohen was also responsible for
in-licensing activities for preclinical through Phases 1 to 3
oncology compounds and served as an in-house expert for pediatric
oncology drug development. Prior to joining Novartis, Dr. Cohen
held several academic positions in pediatric oncology at various
institutions, including Cornell, UCLA, the National Cancer
Institute, and Stanford University. Dr. Cohen received her
undergraduate degree from Barnard College, Columbia University and
her medical degree from the Mount Sinai School of Medicine. She has
received many awards and honors and has authored over 30
publications in the area of the molecular biology of pediatric and
medical oncology, clinical development of targeted oncology
therapeutics and the development of biomarkers for use in oncology
drug development. About Kosan Kosan Biosciences is a biotechnology
company advancing two new classes of anticancer agents through
clinical development -- a Hsp90 (heat shock protein 90) inhibitor
and an epothilone. Hsp90 inhibitors have a novel mechanism of
action targeting multiple pathways involved in cancer cell growth
and survival. Tanespimycin (KOS-953) is being tested in combination
with Velcade(R) (bortezomib) in patients with multiple myeloma in a
clinical program called TIME. Tanespimycin is also being studied in
HER2-positive metastatic breast cancer in combination with
Herceptin(R) (trastuzumab). Epothilones inhibit cell division with
a mechanism of action similar to taxanes, one of the most
successful classes of anti-tumor agents. KOS-1584 is in a Phase 2
clinical trial in patients with non-small cell lung cancer. Kosan's
motilin agonist compound, KOS-2187, licensed to Pfizer for
development in gastroesophagel reflux disease, is in a Phase 1
trial. For additional information on Kosan Biosciences, please
visit the company's website at http://www.kosan.com/. This press
release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995 (the "Act"). Such forward-looking statements
include but are not limited to statements regarding the further
development and potential safety, efficacy, regulatory status,
commercial potential and other characteristics of Kosan's product
candidates; the continuation of current clinical trials; the
initiation of additional clinical trials and the timing thereof and
the use of Kosan's financial resources. Words such as "will,"
"expect," "believe," "may," "intend," "plan," "potential" and
similar expressions are intended to identify forward-looking
statements. Any statements contained in this press release that are
not statements of historical fact may be deemed to be
forward-looking statements. These forward-looking statements are
based upon Kosan's current expectations. Forward-looking statements
involve risks and uncertainties. Kosan's actual results and the
timing of events could differ materially from those anticipated in
such forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, risks related to
the uncertain progress and results of Kosan's preclinical and
clinical testing, including the risks that studies and trials may
not demonstrate safety and efficacy sufficient to initiate clinical
trials on the timing currently anticipated, or at all, continue
clinical development, obtain the requisite regulatory approvals or
result in a marketable product; the conduct of clinical trials;
manufacturing; regulatory approval requirements and process; the
effort and expense necessary for further development of Kosan's
product candidates, including the costs of bortezomib; intellectual
property matters, including Kosan's ability to obtain valid and
enforceable patents covering its product candidates; Kosan's
dependence on its collaboration with Pfizer for development of its
motilin agonist product candidate; Kosan's need for additional
financing and Kosan's strategy to enter into partnering or
licensing arrangements. These and other risk factors are discussed
under "Risk Factors" in Kosan's Annual Report on Form 10-K for the
year ended December 31, 2007 and other periodic filings with the
SEC. Kosan expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein. Velcade(R) (bortezomib) is a
registered trademark of Millennium Pharmaceuticals, Inc.
Herceptin(R) (trastuzumab) is a registered trademark of Genentech,
Inc. DATASOURCE: Kosan Biosciences Incorporated CONTACT: Jane
Green, VP, Corporate Communications of Kosan Biosciences
Incorporated, +1-510-731-5335, mobile, +1-415-652-4819, Web site:
http://www.kosan.com/
Copyright
Kosan Biosciences (MM) (NASDAQ:KOSN)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Kosan Biosciences (MM) (NASDAQ:KOSN)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024